Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis

Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today reports... | March 10, 2022

Related Keywords

Germany ,Japan ,Paris ,France General ,France ,Hungary ,United Kingdom ,Belgium ,Italy ,Poland ,Spain ,Hartmutj Ehrlich ,William Robinson ,Enregistrement Universel ,Paul Emery ,Division Of Immunology ,Leeds Teaching Hospitals ,Leeds Musculoskeletal Biomedical Research Centre ,American College Of Rheumatology ,Leeds Institute Of Rheumatic ,Stanford University ,Euronext ,Euronext Paris ,Versus Arthritis Professor ,Leeds Teaching Hospitals Trust ,Leeds Institute ,Musculoskeletal Medicine ,French Autorit ,Des March ,American College ,Disease Activity Score ,Abivax Stock Exchange ,News ,Information ,Press Release ,Abivax ,Biotechnology ,Company ,Developing ,Novel ,Therapies ,Hat ,Modulate ,The ,Immune ,System ,O ,Treat ,Hronic ,Inflammatory ,Viral ,End ,Oday Abvx Fr0012333284 ,